Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.

Logo of the Society for Clinical Trials

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is a large, pragmatic randomised trial for the treatment of hospitalised patients with suspected or confirmed COVID-19. It was designed and implemented at extraordinary speed in the midst of the COVID-19 pandemic, at a time of great need for effective treatments to reduce mortality among hospitalised patients.

Peter Horby, Professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the RECOVERY trial, said ‘This award is a testament and a tribute to the exceptional work of many thousands of people working under the most difficult circumstances. 2020 was awful in so many ways but the RECOVERY trial was uplifting, showing what can be achieved when there is unity, resolve and a commitment to good science. RECOVERY is a truly national achievement and every person involved should feel incredibly proud. I would encourage them to regularly remind themselves that there are many thousands of people who are only alive today thanks to their efforts.’ 

Every year since 2008, the Society for Clinical Trials has awarded the David Sackett Trial of the Year Award to a randomised, controlled trial published in the previous calendar year that best fulfills the following standards: improves the lot of humankind; provides the basis for a substantial, beneficial change in health care; reflects expertise in subject matter, excellence in methodology, and concern for study participants; overcomes obstacles in implementation; and based on the presentation of its design, execution, and results is a model of clarity and intellectual soundness.

The full story is available on the RECOVERY website

Similar stories

Meta-analysis informed the updated WHO guidelines for treatment of uncomplicated malaria in the first trimester of pregnancy

A new WWARN meta-analysis, commissioned by the World Health Organization and which informed a change to its treatment guidelines, has been published in The Lancet. The study provides compelling evidence that artemether-lumefantrine should now replace quinine as the treatment of choice in the first trimester.

Bacterial infections linked to one in eight global deaths, according to GRAM study

Data showing 7.7 million deaths from 33 bacterial infections can guide measures to strengthen health systems, particularly in low-income settings

GRAM visualization tool tracks country-level AMR and related metrics

Interactive app allows users to explore data underlying estimates of global AMR burden

MQRG team delivers training in Mozambique and Ghana

IDDO’s Medicine Quality Research Group delivered in-person training in researchers in Mozambique and Ghana to support a study into the quality of three antibiotics.

Studying the MSc IHTM 2022/23

MSc IHTM sets out to attract individuals from low resource contexts who are looking to gain the skills and experience to help shape global health in the future. This year 23 students make up the cohort bringing the running total over the eight years of the course to 175 students from 56 countries, the majority of which are LMICs.

Abhilasha Karkey, new OUCRU Nepal Director

OUCRU Nepal is pleased to announce that as of 01 October 2022, Dr Abhilasha Karkey will assume the role of Director.